41 results about "Metaplasia" patented technology

Set forth are vascular valves and servovalves and methods of using the same that may be positioned in the circulatory system without interrupting blood flow to facilitate solid organ transplantation so as to reduce graft organ anoxia and degradation before and after harvesting and storage, thereby minimizing late-term cardiac allograft vasculopathy as a major cause of graft failure. Along the urinary tract, bypassing bladder-generated urge sensation by diverting urine directly from the ureters to a neobladder or collection bag alleviates intractable incontinence, nocturia, urethral syndrome, overactive bladder, dysuria, or frequency. Where the lower tract is missing, a prosthesis can thwart disease and preclude the degenerative metaplastic transition to carcinoma risked when gut is used to construct a conduit for urine, a neobladder, and / or high-maintenance stoma. Druglines to valves and servovalves can directly pipeline-target medication to nidi, anastomoses, or any other trouble spots.

A lamb stomach extract Vitamin B12 preparation composition composed of lamb stomach extract and Vitamin B12 is provided. The lamb stomach extract has a chymosin activity of >40 U / g and a pepsin activity of >15 U / g, and the weight ratio of the lamb stomach extract and Vitamin B12 is 100000:0.5-5, which is useful in the treatment of moderate-to-severe chronic atrophic gastritis, intestinal metaplasia reversal, and gastric cancer prevention. Lamb stomach extract and Vitamin B12 produced synergistic or synergistic effects in specific ratios.

The invention relates to the technical field of biological medicine, in particular to a drug screening model construction method based on airway organs, a model and application. The construction method of the drug screening model of the airway organoid comprises the steps of obtaining 2D airway epithelial cells, culturing the airway organoid, establishing an airway organoid inflammation model and / or establishing an airway organoid mucus secretion / goblet cell metaplasia model. Wherein the model is established according to the culture mode of the airway organ in cooperation with a specific stimulant for proliferation and differentiation. Compared with a traditional animal model, the organ-like model is low in cost and short in construction period, can better simulate the pathological process, can realize airway organ-like culture and establishment of an inflammation model and a mucus secretion / goblet cell metaplasia model at the same time, and has a good application prospect in drug detection of asthma and COPD diseases.

Pyrvinium and its derivatives for reprogramming precancerous mucosa into a noncancerous state are described herein. Furthermore, pyrvinium and its derivatives for reducing the risk of cancer development in organisms containing metaplastic or dysplastic cells are described herein.

The invention relates to the technical field of biological medicine, provides novel application of IL-17a, and particularly relates to application of an IL-17a inhibitor in preparation of a medicine for treating age-related olfactory dysfunction. The research result shows that the expression increase of the IL-17a can trigger an inflammation signal and damage the olfactory function. Administration of the IL-17a inhibitor Y-320 or a neutralizing antibody promotes sensory neuron regeneration in the olfactory epithelium (OE) and reverses age-related respiratory metaplasia. In addition, conditional knockout of IL-17a in T cells can promote olfactory epithelium regeneration by promoting recruitment and differentiation of horizontal basal cells (HBCs) into globular basal cells (GBCs). In general, the research of the invention determines the previously undetermined effect of the IL-17a in olfactory epithelium regeneration and age-related olfactory function defects, and provides evidence for the IL-17a as a potential therapeutic target for olfaction of the elderly.

The invention relates to the technical field of biology, in particular to application of black phosphorus nanosheet hydrogel to preparation of medicine for treating dry eye syndrome. The black phosphorus nanosheet hydrogel can promote tear film healing, treat dry corneal injury and remove active oxygen and free radicals, has an anti-inflammatory effect, inhibits squamous metaplasia, inhibits expression of IL-1beta, K10 and MMP-9 and the like, and provides a new direction for treatment of the dry eye syndrome.

The present disclosure is a telescopic endobronchial stem cell cultivation catheter that comprises a segment catheter (1), a terminal catheter (2), and a respiratory catheter (3) ensuring that ensures the prevention of the progression of COPD and provides early treatment before it progresses to advanced stages, allows the increase of the number of reduced lung parenchyma by means of its inoculation feature in advanced COPD stages, provides the removal of metaplastic cells in the bronchial walls in the application area with the rhythmic inflation-deflation movement by means of the balloons (1.2, 2.2, 3.2) and reduces the risk of future cancer formation, and increases respiratory ventilation by expanding narrowed terminal bronchioles (11) and increasing air flow to the respiratory bronchioles (12).

This invention is directed to methods of reducing incidence or reducing severity or preventing progression of or preventing or treating or preventing pathogenesis of a cancer in a subject, wherein said subject is predisposed to, showing early indications of or suffering from cancer, or methods of reducing intracellular bacterial infection in subjects at risk for or suffering from carcinoma, or from pre-neoplastic or metaplastic tissue changes, comprising contacting at least one cell in an affected tissue in said subject with an agent reducing intracellular bacterial infection in affected tissue, reducing localization of intracellular bacteria proximally to nuclei in cells of affected tissue, or a combination thereof. This invention is further directed to methods of personalized optimized diagnosis and therapy in a subject, comprising screening a subject predisposed to, or at risk for cancer and identifying whether the pre-cancerous or cancerous tissue in the subject is intracellularly infected with bacteria, optionally assessing the intracellular localization of the bacteria-containing compartment to determine a distance of same from a nucleus in the cell; optionally assessing the oncogene profile expression in the subject, and further scoring the subject in terms of the prognosis and potential for therapy and then treating the subject to reduce the intracellular bacterial burden, promote re-localization of the bacterial compartment to be at a further distance from the nucleus, successfully eradicate intracellular bacterial infection, prevent or reduce cell-to-cell spread of the bacteria or any combination thereof. Compositions and kits for effecting the methods of this invention are also provided. This invention still further provides a system for identifying patients who would benefit from adjunctive antimicrobial therapies, enhancing treatment outcomes by providing comprehensive microbial feature characterization, including spatial localization of key microbes associated with treatment resistance in an integrated platform with advanced machine learning algorithms, ultimately providing a personalized patient assessment, enhancing treatment outcomes and optimizing therapeutic strategies.

The application belongs to the field of biological medicine, and particularly relates to application of DJ-1 in treatment and diagnosis of bronchial asthma. DJ-1 is used as a target in preparation or screening of drugs for bronchial asthma or allergic inflammation; a drug for treating hyperplasia of goblet cells and mucus metaplasia in bronchial asthma, and an animal model for studying inhibition of differentiation of goblet cells and mucus metaplasia. The application identifies, for the first time, an important role of a signal pathway DJ-1 / Ltc4s, which has not been found in eosinophils and lung epithelial cells before, in differentiation of secretory cells into goblet cells, and finds, for the first time, an inhibitory effect of inhibition of the DJ-1 / Ltc4s signal pathway on differentiation of goblet cells in lung epithelial cells through a large number of studies.

The invention provides a traditional Chinese medicine composition for treating chronic atrophic gastritis and a preparation method thereof. The traditional Chinese medicine composition comprises the following raw material medicines in parts by weight: 280-320 parts of red ginseng; the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 580 to 620 parts of rhizoma atractylodis macrocephalae, 280 to 320 parts of rhizoma zingiberis, 80 to 120 parts of sandalwood, 280 to 320 parts of edible tulip, 580 to 620 parts of concha arcae, 580 to 620 parts of oldenlandia diffusa, 180 to 220 parts of notholirion bulbuliferum and 280 to 320 parts of sea buckthron oil. The total effective rate of the traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia is 93%, and the traditional Chinese medicine composition has a remarkable clinical effect on treating chronic atrophic gastritis with intestinal metaplasia clinically.

The invention provides application of combination of an mTOR inhibitor and an EPAS1 inhibitor in preparation of a medicine for treating myeloproliferative tumors, through combined use of the mTOR inhibitor everolimus and the EPAS1 inhibitor PT2385, JAK2V617F mutation-driven metabolic disorder is targeted, metabolic reprogramming is effectively reversed (the lactic acid level is reduced, the alpha-ketoglutaric acid level is increased, and the lactic acid / alpha-KG ratio is corrected), and the treatment effect on myeloproliferative tumors is improved. The JAK inhibitor can be used for treating MPN, synergistically relieving splenomegaly, reversing myelofibrosis and reducing mutation allele load, the curative effect is remarkably superior to that of existing JAK inhibitor single-drug treatment, and an innovative scheme with disease modification potential is provided for MPN.

The present disclosure provides methods and formulations for treating a patient suffering from one or more of chronic inflammatory injury, metaplasia, dysplasia or cancer of esophageal tissue and gastric tissue, which method comprises administering to the patient an agent that selectively kills or inhibits the proliferation or differentiation of pathogenic Barrett's Esophagus stem cells (BESCs) or Gastric Intestinal Metaplasia stem cells (GIMSCs) relative to normal regenerative esophageal stem cells or gastric stem cells in the tissue in which the BESCs or GIMSCs are found.

Disclosed herein are methods for treating Barrett's metaplasia and esophageal adenocarcinoma and methods for determining mutational load as a predictor of the risk of disease progression from Barrett's metaplasia to esophageal adenocarcinoma.

The invention relates to the field of epigastric pain treatment, in particular to a repairing medicament for treating epigastric pain atrophic gastritis with erosion and intestinal metaplasia. Comprising the following components in parts by weight: 10-20 parts of radix bupleuri, 10-20 parts of radix paeoniae alba, 10-20 parts of fructus aurantii immaturus, 8-12 parts of raw liquorice, 10-20 parts of rhizoma atractylodis macrocephalae, 10-20 parts of poria cocos, 10-20 parts of radix pseudostellariae, 10-20 parts of radix angelicae sinensis, 10-20 parts of ligusticum wallichii, 10-20 parts of radix rehmanniae preparata, 10-20 parts of radix aucklandiae, 10-20 parts of pawpaw, 10-20 parts of fructus aurantii, 10-20 parts of radix linderae, 20-40 parts of lily, 15-25 parts of rhizoma corydalis, 15-25 parts of radix salviae miltiorrhizae, 15-25 parts of dandelion, 15-25 parts of white flower herb, 10-20 parts of rhizoma bletillae and 10-20 parts of radix notoginseng. The traditional Chinese medicine is prepared from the following raw materials in parts by weight: 20-40 parts of cuttlebone, 20-40 parts of corrugated shells, 15-25 parts of curcuma zedoary, 20-40 parts of endothelium corneum gigeriae galli, 15-25 parts of thunberg fritillary bulb, 15-25 parts of oyster, 10-20 parts of coptis chinensis and 15-20 parts of serissa serissoide. The radix bupleuri and the fructus aurantii immaturus are used for soothing the liver and regulating qi, the rhizoma atractylodis macrocephalae and the poria cocos are matched for strengthening the spleen and eliminating dampness, and improving qi stagnation of the spleen and the stomach, and a plurality of dosage forms are adopted in the preparation mode, so that decoction, oral thick paste, powder, pills and tablets can be provided to meet the requirements of different patients.

The invention provides an absorbable multifunctional Janus structure urethrostenosis repair material and a preparation method thereof, and belongs to the technical field of medical materials, the absorbable multifunctional Janus structure urethrostenosis repair material comprises a hydrophilic layer and a hydrophobic layer which are tightly connected; the hydrophilic layer is prepared from polyvinylpyrrolidone through electrostatic spinning; the hydrophobic layer is prepared from polycaprolactone through electrostatic spinning; the hydrophilic layer and the hydrophobic layer are tightly connected through a transition structure formed by electrostatic spinning at the same time; each layer is loaded with drugs, the hydrophilic layer is in contact with in-vivo tissues and can release anti-inflammatory drugs and growth factors and promote urethral tissue repair, and the hydrophobic layer is used for isolating urine, so that the urine is discharged smoothly and wound infection is prevented. The urethrostenosis repair material provided by the invention can improve the problem of urethrostenosis recurrence caused by urethral epithelium squamous metaplasia, fibrosis, inflammatory hyperplasia and the like easily caused by the existing urethrostenosis treatment means, and reduces the recurrence rate of urethrostenosis.

The present disclosure is a telescopic endobronchial stem cell cultivation catheter that comprises a segment catheter (1), a terminal catheter (2), and a respiratory catheter (3) ensuring that ensures the prevention of the progression of COPD and provides early treatment before it progresses to advanced stages, allows the increase of the number of reduced lung parenchyma by means of its inoculation feature in advanced COPD stages, provides the removal of metaplastic cells in the bronchial walls in the application area with the rhythmic inflation-deflation movement by means of the balloons (1.2, 2.2, 3.2) and reduces the risk of future cancer formation, and increases respiratory ventilation by expanding narrowed terminal bronchioles (11) and increasing air flow to the respiratory bronchioles (12).

The invention belongs to the technical field of biological medicine, discloses nanocapsule-loaded in-situ gel for treating H. pylori infection and reversing intestinal metaplasia of gastric tissue and application of the nanocapsule-loaded in-situ gel, and particularly discloses nanocapsule-loaded in-situ gel which comprises a nanocapsule and pH-responsive gel, the nanocapsule is dispersed in the gel, and the pH-responsive gel is a pH-responsive gel. Comprising an active drug, a macromolecular substance for coating the active drug and a structure stabilizer. According to the nanocapsule-loaded in-situ gel provided by the invention, the nanocapsule-loaded in-situ gel is directionally released on one side by responding to the change of the pH value of an H.pylori infected part, and the nanocapsule responds to lipase secreted by H.pylori to accurately release an active drug, so that efficient sterilization is realized, and damage caused by infection is relieved. Meanwhile, the gel can also effectively reverse gastrointestinal metaplasia caused by H.pylori infection, further reduces the risk of gastric cancer, and provides a new thought for gastric cancer prevention.

The invention discloses a mass-eliminating composition for treating gastric precancerous lesions as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The composition for eliminating mass comprises astragalus membranaceus, dragon's blood, cassia twig, poria cocos, radix paeoniae alba, perilla stem, immature bitter orange, mangnolia officinalis, rhizoma nardostachyos, oldenlandia diffusa, cuttlebone, thunberg fritillary bulb, pseudo-ginseng, rheum officinale, dark plum and honey-fried licorice root. Through the steps of decocting twice, concentrating into thick paste and the like, the mass-eliminating composition disclosed by the invention is prepared into the medicine for treating precancerous lesions of gastric cancer. Clinical experiment results show that the medicine provided by the invention can effectively relieve symptoms such as gastral cavity pain, sour regurgitation and the like of patients with precancerous lesions of gastric cancer, can also remarkably improve the degree of gastric mucosa atrophy, intestinal metaplasia and atypical hyperplasia, is high in safety and low in toxic and side effects, and is comprehensively superior to traditional prescriptions. The invention provides a novel medicine composition for treating precancerous lesions of gastric cancer and preventing gastric cancer, and has outstanding clinical application value and wide application prospect.

The invention provides an M2 macrophage exosome loaded canagliflozin nano-drug and application thereof, an M2 macrophage exosome is used as a carrier, and canagliflozin is loaded on the M2 macrophage exosome. The Exo-CANA delivery system is constructed for the first time, the exosomes are small in size, the phagocytosis of mononuclear macrophages can be effectively avoided, the exosomes can freely penetrate through vascular walls and extracellular matrixes, Th2 type airway inflammation, goblet cell metaplasia and pulmonary interstitial collagen deposition can be remarkably improved, and the treatment effect is remarkably superior to that of a CANA single-drug treatment group and an M2-Exos single-drug treatment group.

According to the present invention, strains for preventing gastric cancer have been identified and, in particular, it has been identified that when a microbiome was administered together with H. felis, which is known to cause various gastrointestinal diseases by inducing gastric tissue damage and inflammatory responses, gastric tissue damage and inflammatory responses did not occur. Furthermore, it has been identified that the microbiome suppresses gastric tissue damage when administered even in cases already infected with H. felis. Therefore, the microbiome can be effectively used as a preventive or therapeutic agent for normalizing gastric intestinal metaplasia, which is a precancerous lesion, and for suppressing gastric carcinogenesis.

This invention proposes a grading system for the severity of intestinal metaplasia based on the deformation Transformer. By dividing the endoscopic image into multiple feature units, matching feature unit groups are obtained based on the similarity of the feature units. The feature unit groups are then fused after weight calculation, realizing the deformation of the sampling region in the Transformer. This overcomes the shortcomings of the fixed region sampling in the Transformer, improves the feature extraction capability, and enhances the accuracy of grading the severity of intestinal metaplasia.

A method for detecting methylation status of at least one sequence in a tissue sample of a subject includes providing the tissue sample obtained from the subject, treating the tissue sample to convert DNA sequences within the tissue sample with at least one of enzymatic conversion and chemical conversion to produce a modified sample having converted DNA sequences and replicated the converted DNA. The method further includes amplifying the converted DNA sequences to provide a plurality of converted amplicons and analyzing the plurality of converted amplicons to determine the methylation status of the sample.

It has been identified in the present invention that, in addition to Helicobacter felis, strains causing cell hyperplasia, metaplasia, dysplasia, and the like in gastric tissues. Therefore, a gastric cancer mouse model in which gastric lesions are induced in mice can be provided using a gastric microbial transplantation (GMT) technology, and various gastrointestinal diseases can be diagnosed and the prognosis thereof can be predicted by measuring the concentrations of the strains.

The invention discloses a construction method of a chronic atrophic gastritis precancerous lesion animal model, and the construction method comprises the following specific steps: selecting experimental mice, randomly and averagely dividing the experimental mice into a model group and a blank control group, the experimental mice of the model group drink an MNU solution I by themselves and use an MNU solution II for intragastric administration once a week, and the blank control group normally diets; after modeling, dissecting and taking stomach tissues for later use; the MNU solution I is an N-nitroso-N-methylurea solution with the concentration of 290 mg / L to 310 mg / L; the MNU solution II is an N-nitroso-N-methylurea solution with the concentration of 1.6 g / L to 1.7 g / L; according to the method, 14-week modeling can be achieved, intestinal metaplasia, heterodysplasia and even a small number of cancer cells can occur in 14 weeks, and compared with a traditional MNNG combined multi-factor modeling method, the modeling method has the advantages that the modeling method is simplified, experimental errors and individual differences are reduced, the modeling period is shortened, and the modeling success rate is increased.

Recombinant blood group antigen-binding adhesin (BabA) can be used in a composition to raise humoral immune response i.e. antibodies, that target conserved structural epitopes in the fucosylated blood group antigen Lewis b (Leb) antigen binding domain in the blood group antigen-binding adhesin (BabA). Such broadly Leb-blocking antibodies can reduce the gastric mucosal attachment of Helicobacter pylori (H. pylori) to human gastric mucosa. This approach can be used for preventing and / or alleviating gastric disease in a subject diagnosed with H. pylori infection, said gastric disease chosen from gastroesophageal reflux disease, chronic active gastritis, peptic ulcer diseases, gastric ulcer disease, gastric cancer gastritis and gastric cancer, in particular gastric cancer. It also becomes possible to identify subjects that carry BabA positive H. pylori infections and subjects that are at risk of developing severe gastric disease, such as peptic ulcer diseases, gastric ulcer disease, gastritis with metaplasia and gastric cancer.

The invention discloses a traditional Chinese medicine composition and application thereof, raw material medicines of the traditional Chinese medicine composition comprise first raw material medicines, and the first raw material medicines comprise 10-40 parts by weight of mangnolia officinalis, 10-60 parts by weight of astragalus membranaceus, 10-40 parts by weight of bighead atractylodes rhizome, 10-40 parts by weight of curcuma zedoary, 5-40 parts by weight of rhizoma bletillae and 5-40 parts by weight of rhizoma zingiberis; the raw material medicine of the traditional Chinese medicine composition further comprises a second raw material medicine, and the second raw material medicine is pseudo-ginseng; the weight ratio of the first raw material medicine to the second raw material medicine is (15-17): (1-12). The traditional Chinese medicine composition can effectively relieve digestive tract discomfort symptoms caused by chronic atrophic gastritis, can effectively improve the pathological state of gastrointestinal tract tissues, reverses the pathological states of stomach tissue atrophy, intestinal metaplasia and / or dysplasia and the like, relieves gastrointestinal tract disease symptoms such as poor appetite, abdominal distension, fullness, belching, sour regurgitation and heartburn in the past, and improves the curative effect of chronic atrophic gastritis. And the traditional Chinese medicine composition is simple in taking method, low in dosage and high in clinical value.

The invention belongs to the technical field of medical experimental animal models, and particularly relates to a construction method of a spleen and stomach damp-heat syndrome chronic atrophic gastritis animal model. The construction method comprises the following steps: firstly, performing spleen and stomach damp-heat modeling on a tested animal to obtain spleen and stomach damp-heat syndromes, and then performing chronic atrophic gastritis induction. According to the specific three-step atrophic gastritis induction method, the clinical pathological process of inflammation caused by stimulation, gastric mucosa atrophy caused by damp heat and blood stasis for a long time and intestinal metaplasia can be accurately copied, the clinical pathological process is highly matched with the stage progress characteristic of clinical chronic atrophic gastritis, and the model is high in success rate, good in stability and high in repeatability.

The invention relates to the technical field of medicines, in particular to application of polypeptide in prevention and / or treatment of gastrointestinal metaplasia. The polypeptide with the amino acid sequence of KIVFILCAAAAIVTRKT is found and verified for the first time and can target a molecular polypeptide of an intestinal key transcription factor CDX2 and a downstream signal channel of the CDX2, expression of the CDX2 and expression of the downstream signal channel of the CDX2 can be inhibited, expression of a stomach type marker can be promoted, the pathological process of GIM can be effectively reversed, and the GIM can be used for preparing a medicine for treating intestinal diseases. Compared with medicines which can only relieve symptoms or delay progression in the prior art, the medicine can realize pathological reversion of the GIM, so that a new direction can be provided for development of intervention medicines of the GIM.

The invention discloses a traditional Chinese medicine composition and application thereof in preparing a medicine for treating chronic atrophic gastritis and intestinal metaplasia. The traditional Chinese medicine composition is prepared from, by weight, 10-15 parts of radix pseudostellariae, 6-10 parts of poria cocos, 10-15 parts of roasted rhizoma atractylodis macrocephalae, 10-12 parts of pericarpium citri reticulatae, 6-9 parts of ginger processed pinellia, 10-15 parts of radix salviae miltiorrhizae, 15-30 parts of semen coicis, 15-30 parts of radix actinidiae chinensis, 10-15 parts of oldenlandia diffusa, 15 parts of actinidia valvata, 15-30 parts of wild grape roots, 2-3 parts of gecko and 3-6 parts of honey-fried licorice roots. The invention provides a new thought for early treatment of gastric mucosa atrophy and intestinal metaplasia so as to reduce the occurrence risk of gastric cancer and improve the living quality of patients.

The invention discloses a cervical cancer differential diagnosis method based on GINS1 expression quantity. The cervical cancer differential diagnosis method comprises the following steps: S1, acquiring a cell or tissue sample in a to-be-detected sample and pre-treating the cell or tissue sample; s2, measuring the expression quantity of the GINS1 gene in the sample; s3, comparing the measured GINS1 expression quantity with the known cervical cancer sample expression quantity; s4, judging whether the to-be-detected sample is cervical cancer or not according to a comparison result; by integrating the expression level, functional activity and spatial distribution characteristics of the GINS1 gene, a multi-modal detection system is constructed, and the multi-dimensional analysis not only can effectively distinguish cervical cancer from benign lesions (such as inflammation or metaplasia), but also can identify the molecular characteristics of a small number of abnormal cells in early cancerization, so that the detection result is more accurate. The problem of misdiagnosis caused by limitation of a single index in the prior art is solved; a DNA damage response dynamic correction mechanism is innovatively introduced, and a GINS1 judgment threshold is automatically adjusted by evaluating the DNA damage degree in a sample in real time, so that a diagnostic standard has environmental adaptability.